HCW Biologics Inc. (NASDAQ:HCWB – Get Free Report)’s share price rose 1.2% on Tuesday . The stock traded as high as $0.44 and last traded at $0.41. Approximately 226,408 shares traded hands during mid-day trading, a decline of 2% from the average daily volume of 230,527 shares. The stock had previously closed at $0.41.
HCW Biologics Trading Down 2.4 %
The business has a 50-day simple moving average of $0.47 and a 200-day simple moving average of $0.53. The company has a market cap of $15.13 million, a PE ratio of -0.40 and a beta of 0.87. The company has a quick ratio of 0.07, a current ratio of 0.07 and a debt-to-equity ratio of 0.95.
About HCW Biologics
HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
Read More
- Five stocks we like better than HCW Biologics
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- What is a Secondary Public Offering? What Investors Need to Know
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Which Wall Street Analysts are the Most Accurate?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
